End-of-day quote
Korea S.E.
18:00:00 2024-04-28 EDT
|
5-day change
|
1st Jan Change
|
38,700
KRW
|
+0.39%
|
|
+5.16%
|
-0.77%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
785,088
|
1,665,449
|
1,563,338
|
1,932,235
|
347,646
|
1,153,908
|
Enterprise Value (EV)
1 |
724,919
|
1,627,887
|
1,519,338
|
1,889,061
|
318,961
|
1,096,162
|
P/E ratio
|
-40.5
x
|
-71.2
x
|
-110
x
|
-142
x
|
-9.57
x
|
-86.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
41.1
x
|
88
x
|
54.6
x
|
72.5
x
|
11.3
x
|
36.4
x
|
EV / Revenue
|
38
x
|
86
x
|
53.1
x
|
70.9
x
|
10.4
x
|
34.6
x
|
EV / EBITDA
|
-33.4
x
|
-70.5
x
|
-249
x
|
-124
x
|
-14.7
x
|
-84.7
x
|
EV / FCF
|
-117
x
|
-75.8
x
|
-137
x
|
-108
x
|
-74.4
x
|
-61
x
|
FCF Yield
|
-0.86%
|
-1.32%
|
-0.73%
|
-0.92%
|
-1.34%
|
-1.64%
|
Price to Book
|
13.8
x
|
38.9
x
|
27.5
x
|
30.8
x
|
13.2
x
|
18.8
x
|
Nbr of stocks (in thousands)
|
25,601
|
26,118
|
26,678
|
26,701
|
26,742
|
29,587
|
Reference price
2 |
30,667
|
63,767
|
58,600
|
72,367
|
13,000
|
39,000
|
Announcement Date
|
19-03-21
|
20-03-19
|
21-03-23
|
22-03-23
|
23-03-23
|
24-03-18
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
19,088
|
18,931
|
28,634
|
26,654
|
30,726
|
31,721
|
EBITDA
1 |
-21,698
|
-23,093
|
-6,098
|
-15,212
|
-21,673
|
-12,942
|
EBIT
1 |
-21,926
|
-24,425
|
-7,531
|
-16,798
|
-23,331
|
-14,489
|
Operating Margin
|
-114.87%
|
-129.02%
|
-26.3%
|
-63.02%
|
-75.93%
|
-45.68%
|
Earnings before Tax (EBT)
1 |
-20,824
|
-22,220
|
-12,836
|
-13,026
|
-35,910
|
-12,480
|
Net income
1 |
-18,876
|
-23,251
|
-13,829
|
-13,603
|
-36,298
|
-12,728
|
Net margin
|
-98.89%
|
-122.82%
|
-48.3%
|
-51.03%
|
-118.13%
|
-40.13%
|
EPS
2 |
-757.5
|
-895.2
|
-532.0
|
-509.7
|
-1,358
|
-451.0
|
Free Cash Flow
1 |
-6,219
|
-21,479
|
-11,123
|
-17,413
|
-4,290
|
-17,965
|
FCF margin
|
-32.58%
|
-113.46%
|
-38.85%
|
-65.33%
|
-13.96%
|
-56.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-21
|
20-03-19
|
21-03-23
|
22-03-23
|
23-03-23
|
24-03-18
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
60,169
|
37,562
|
44,000
|
43,173
|
28,685
|
57,747
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-6,219
|
-21,479
|
-11,123
|
-17,413
|
-4,290
|
-17,965
|
ROE (net income / shareholders' equity)
|
-34.2%
|
-46.4%
|
-27.8%
|
-22.7%
|
-81.5%
|
-29%
|
ROA (Net income/ Total Assets)
|
-18.4%
|
-22.8%
|
-7%
|
-13.2%
|
-21.1%
|
-12.4%
|
Assets
1 |
102,688
|
102,000
|
197,601
|
103,370
|
171,702
|
102,731
|
Book Value Per Share
2 |
2,226
|
1,640
|
2,129
|
2,352
|
981.0
|
2,075
|
Cash Flow per Share
2 |
1,148
|
599.0
|
1,344
|
907.0
|
1,099
|
1,359
|
Capex
1 |
572
|
1,098
|
774
|
358
|
768
|
529
|
Capex / Sales
|
3%
|
5.8%
|
2.7%
|
1.34%
|
2.5%
|
1.67%
|
Announcement Date
|
19-03-21
|
20-03-19
|
21-03-23
|
22-03-23
|
23-03-23
|
24-03-18
|
|
1st Jan change
|
Capi.
|
---|
| -0.77% | 836M | | +3.82% | 69.85B | | +11.77% | 8.98B | | -14.44% | 4.89B | | +41.60% | 4.44B | | +5.96% | 3.95B | | +22.45% | 2.49B | | -19.32% | 2.4B | | -27.04% | 2.28B | | +7.97% | 1.96B |
Specialty & Advanced Pharmaceuticals
|